Rebecca Over, DO
Endocrinology, Diabetes & Metabolism · Tacoma, WANPI 1548428683
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,283 of the $6,105 with a category attached, or 86.5%. It is spread thinly across 38 manufacturers, the largest accounting for just 17.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,857 and has fallen 91.5% since, to $157 in 2025.
Across 275 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Novo Nordisk$565
- Amgen$556
- Boehringer Ingelheim$523
- Abbott$291
- Johnson & Johnson$277
- plus $3K from 32 others
What the payments were for
- Travel & lodging$78213%
- Food & beverage$5,28387%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 20 | $1,064 |
| Novo Nordisk | 15 | $565 |
| Amgen(2 entities) | 17 | $556 |
| Boehringer Ingelheim | 30 | $523 |
| Abbott | 14 | $291 |
| Johnson & Johnson(2 entities) | 33 | $277 |
| Sanofi-aventis U.S. LLC | 14 | $275 |
| Lilly USA, LLC | 13 | $247 |
| Merck | 18 | $243 |
| Dexcom, Inc. | 9 | $233 |
| AstraZeneca | 12 | $213 |
| Insulet Corporation | 8 | $190 |
| Recordati_rare_diseases_inc. | 5 | $165 |
| Corcept Therapeutics | 7 | $162 |
| Antares Pharma, Inc. | 8 | $131 |
| Lifescan, Inc. | 5 | $98 |
| IBSA Pharma Inc. | 5 | $96 |
| Radius Health, Inc. | 5 | $90 |
| Bayer | 4 | $87 |
| AbbVie(2 entities) | 6 | $86 |
| Amryt Pharma Holdings Ltd | 2 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $52 |
| Kowa Pharmaceuticals America, Inc. | 3 | $50 |
| EUSA Pharma (US) LLC | 2 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $37 |
| Novartis | 2 | $30 |
| Kyowa Kirin, Inc. | 1 | $30 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| Medicure Pharma Inc. | 1 | $22 |
| Tandem Diabetes Care, Inc. | 2 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Mannkind Corporation | 1 | $16 |
| BETA Bionics, Inc. | 1 | $15 |
| Halozyme Inc | 1 | $14 |
| Companion Medical, Inc. | 1 | $14 |
| Cequr Corporation | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$697
- Macrilen$275
- EVENITY$233
- RYBELSUS$102
How this compares
$6,105 in reported general payments places this provider in the 75th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 327 | $516,305 |
| JardianceEmpagliflozin | 164 | $199,837 |
| MounjaroTirzepatide | 139 | $190,355 |
| GenotropinSomatropin | 41 | $103,006 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 60 | $96,466 |
| TymlosAbaloparatide | 22 | $90,140 |
| TrulicityDulaglutide | 64 | $87,034 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $86,052 |
| Humalog Kwikpen U-200Insulin Lispro | 28 | $83,412 |
| FarxigaDapagliflozin Propanediol | 85 | $81,355 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 34 | $62,136 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $33,518 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $30,603 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $21,821 |
| Humalog Kwikpen U-100Insulin Lispro | 55 | $20,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $565 | $520,562343 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $247 | $292,012261 claims |
| Boehringer IngelheimJardiance, Tradjenta | $523 | $206,964177 claims |
| Radius Health, Inc.Tymlos | $90 | $90,14022 claims |
| AstraZenecaFarxiga | $213 | $81,35585 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $275 | $15,34311 claims |
| MerckJanuvia | $243 | $12,78917 claims |
| AbbVieSynthroid | $86 | $6,32472 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
Other endocrinology, diabetes & metabolism in Tacoma
- Ronald GrafTacoma$13K
- Gabriela Loperena OropezaTacoma$12K
- Ayesha JameelTacoma$9K
- Rani KulkarniTacoma$3K
- Qin OuyangTacoma$2K
- Zhiyu WangTacoma$2K
- Dali ChenTacoma$2K
- Michael ShannonLacey$698K
- Lynn KohlmeierSpokane$518K
- Carol WyshamSpokane$512K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.